Researchers discover neuronal targets that restore movement in Parkinson's disease model

May 8, 2017, Carnegie Mellon University
Immunohistochemistry for alpha-synuclein showing positive staining (brown) of an intraneural Lewy-body in the Substantia nigra in Parkinson's disease. Credit: Wikipedia

Researchers working in the lab of Carnegie Mellon University neuroscientist Aryn Gittis, have identified two groups of neurons that can be turned on and off to alleviate the movement-related symptoms of Parkinson's disease. The activation of these cells in the basal ganglia relieves symptoms for much longer than current therapies, like deep brain stimulation and pharmaceuticals.

The study, completed in a of Parkinson's, used optogenetics to better understand the neural circuitry involved in Parkinson's disease, and could provide the basis for new experimental treatment protocols. The findings, published by researchers from Carnegie Mellon, the University of Pittsburgh and the joint CMU/Pitt Center for the Neural Basis of Cognition (CNBC) are available as an Advance Online Publication on Nature Neuroscience's website.

Parkinson's disease is caused when the that feed into the brain's die and cause the basal to stop working, preventing the body from initiating voluntary movement. The basal ganglia is the main clinical target for treating Parkinson's disease, but currently used therapies do not offer long-term solutions.

"A major limitation of Parkinson's disease treatments is that they provide transient relief of symptoms. Symptoms can return rapidly if a drug dose is missed or if is discontinued," said Gittis, assistant professor of biological sciences in the Mellon College of Science and member of Carnegie Mellon's BrainHub neuroscience initiative and the CNBC. "There is no existing therapeutic strategy for long lasting relief of movement disorders associated with Parkinson's."

To better understand how the neurons in the basal ganglia behave in Parkinson's, Gittis and colleagues looked at the inner circuitry of the basal ganglia. They chose to study one of the structures that makes up that region of the brain, a nucleus called the external globus pallidus (GPe). The GPe is known to contribute to suppressing motor pathways in the basal ganglia, but little is known about the individual types of neurons present in the GPe, their role in Parkinson's disease or their therapeutic potential.

The research group used optogenetics, a technique that turns genetically tagged cells on and off with light. They targeted two cell types in a mouse model for Parkinson's disease: PV-GPe neurons and Lhx6-GPe neurons. They found that by elevating the activity of PV-GPe neurons over the activity of the Lhx6-GPe , they were able to stop aberrant neuronal behavior in the basal ganglia and restore movement in the mouse model for at least four hours—significantly longer than current treatments.

While optogenetics is used only in animal models, Gittis said she believes their findings could create a new, more effective deep brain stimulation protocol.

Explore further: Parkinson's in a dish: Researchers reproduce brain oscillations

More information: Cell-specific pallidal intervention induces long-lasting motor recovery in dopamine-depleted mice, Nature Neuroscience (2017). nature.com/articles/doi:10.1038/nn.4559

Related Stories

Parkinson's in a dish: Researchers reproduce brain oscillations

May 2, 2017
Abnormal oscillations in neurons that control movement, which likely cause the tremors that characterize Parkinson's disease, have long been reported in patients with the disease. Now, University at Buffalo researchers working ...

New brain stimulation target identified for Tourette syndrome

March 4, 2016
Specifically targeted deep-brain stimulation improves symptoms in patients with severe Tourette, a study reports in the current issue of Biological Psychiatry.

Scientists visualize critical part of basal ganglia pathways

August 17, 2015
Certain diseases, like Parkinson's and Huntingdon's disease, are associated with damage to the pathways between the brain's basal ganglia regions. The basal ganglia sits at the base of the brain and is responsible for, among ...

Conversion of brain cells offers hope for Parkinson's patients

April 11, 2017
Researchers at Karolinska Institutet have made significant progress in the search for new treatments for Parkinson's disease. By manipulating the gene expression of non-neuronal cells in the brain, they were able to produce ...

Brain's role in Tourette tics simulated in new computational model

March 30, 2017
A new computer-based brain simulation shows that motor tics in Tourette syndrome may arise from interactions between multiple areas of the brain, rather than a single malfunctioning area, according to a study published in ...

Recommended for you

New evidence sheds light on how Parkinson's disease may happen

June 14, 2018
Researchers at Baylor College of Medicine and Texas Children's Hospital have identified unexpected new key players in the development of an early onset form of Parkinson's disease called Parkinsonism. These key players are ...

Scientists unravel molecular mechanisms of Parkinson's disease

June 12, 2018
Detailed brain cell analysis has helped researchers uncover new mechanisms thought to underlie Parkinson's disease.

First photoactive drug to fight Parkinson's disease

June 8, 2018
An international team has designed the first potentially therapeutic photoactive drug, MRS7145, to fight Parkinson's disease, according to the new article in Journal of Controlled Release.

Researchers address sleep problems in Parkinson's disease

June 7, 2018
A team of researchers at VIB and KU Leuven has uncovered why people with a hereditary form of Parkinson's disease suffer from sleep disturbances. The molecular mechanisms uncovered in fruit flies and human stem cells also ...

Drugs that suppress immune system may protect against Parkinson's

May 31, 2018
People who take drugs that suppress the immune system are less likely to develop Parkinson's disease, according to a study from Washington University School of Medicine in St. Louis.

Early synaptic dysfunction found in Parkinson's Disease

May 24, 2018
Northwestern Medicine scientists identified a cellular mechanism that leads to neurodegeneration in patients with Parkinson's disease, according to a study published in Proceedings of the National Academy of Sciences.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.